Natera Oncology

Together with Quantum Leap Healthcare Collaborative, we’re excited to share that new findings from the I-SPY 2 trial were recently published in Nature Communications. This publication shows Signatera™ can predict treatment response and recurrence risk in early-stage breast cancer. The study examined how Signatera can refine risk assessment in patients with early-stage breast cancer whose tumors resist neoadjuvant therapy (NAT). Distinguishing which NAT-resistant tumors are more likely to recur could guide treatment decisions to potentially prevent or delay metastatic recurrence. We are grateful for our ongoing collaboration with the I-SPY investigators on research that brings us closer to more personalized and effective care for patients. Read more in our press release: https://ow.ly/YsXj50XKleR

Join experts Laura Bukavina, MD, MPH and Shilpa Gupta, MD from Cleveland Clinic with moderator Adam ElNaggar, MD, FACOG in this live AUANewsWorthy Webinar on December 16. Learn more about tumor-informed ctDNA testing (Signatera™) and its expanding role in guiding clinical decisions across the genitourinary oncology continuum. Register here: https://ow.ly/NTMW50XAYwZ American Urological Association

Today, Natera announced the acquisition of Foresight Diagnostics, a leader in ultrasensitive MRD detection. This combination brings together Foresight’s phased variant technology with Natera’s Signatera™ platform to further strengthen performance across both solid tumors and hematologic cancers. Founded in 2020 by physicians and scientists from Stanford University, Foresight has developed MRD assays using an innovative and patented technology, which delivers advanced sensitivity by tracking phased variants. With this approach, Foresight has detected ctDNA at ultrasensitive levels. The integration of phased variants into Signatera is now available for research use and is expected to launch clinically in 2026. The acquisition also expands our leadership in lymphoma, where Foresight has built a strong scientific foundation, including data that helped drive the inclusion of ctDNA MRD into NCCN® guidelines for diffuse large B-cell lymphoma. At this year’s ASH annual meeting, starting tomorrow, our combined teams will present 15 abstracts, underscoring the momentum behind our approach to personalized MRD testing. We’re excited for the impact this will have on accelerating innovation and improving care for patients worldwide. We’re also thrilled to welcome Foresight and the company’s incredibly talented team to Natera! https://ow.ly/Wqr450XCIgr

Join the upcoming webinar, Signatera™ Ultrasensitive MRD Testing for Head and Neck Cancer Patient Care. Key Takeaways - Learn how ctDNA-based MRD testing can identify recurrence risk and guide treatment decisions in HNSCC - Understand how MRD testing enables earlier detection of recurrence and may predict benefit from immunotherapy - Gain practical insights from real-world case studies and explore future directions in MRD research Register today: https://ow.ly/pxYS50XAknE Featured speakers: Abhinand Peddada, MD Dept. of Radiation Oncology at Pennington Cancer Institute Assistant Clinical Professor Internal Medicine at UNR School of Medicine Michael Krainock, MD, PhD Oncology Medical Director at Natera

Join the upcoming industry spotlight webinar: Ultrasensitive MRD Testing for Post-Surgical Management in NSCLC. Learn how MRD helps identify NSCLC patients who remain at high recurrence risk after surgery and detects recurrence before radiographic imaging. Register today: https://ow.ly/pUob50XAkEj Moderator: Linda W. Martin, MD, MPH University of Virginia, Thoracic and Cardiovascular Surgery  Featured speakers: Leonidas Tapias Tapias, MD, Assistant Professor Thoracic Surgery Thoracic and Esophageal Surgery at University Hospitals Michael Krainock, MD, PhD, Oncology Medical Director at Natera

We're excited to announce an incredibly impactful list of studies highlighting Signatera™ that will be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS) next week. The presentations encompass aggregated data from >50K patients in real-world evidence and prospective clinical studies, demonstrating the prognostic and predictive power of Signatera across diverse breast cancer subtypes and settings. These include real-world studies of Signatera adoption and clinical impact at Yale, Houston Methodist and other leading institutions. Learn more: https://ow.ly/YsP450XASC9 #SABCS25 #Natera San Antonio Breast Cancer Symposium

Kyle’s experience with stage IV colon cancer underscores the role of early detection and personalized care. With the help of Signatera™ MRD testing, Kyle’s care team identified recurrence before imaging could and took swift action. See his full story: https://ow.ly/wpbl50XAbOX #MRDtesting #Natera

It was an honor to support the Get Your Rear in Gear Houston event hosted by Colon Cancer Coalition! Thank you to Ted Echemann, Director of Strategic Accounts, Oncology at Natera who spoke to the crowd of about 800 in the community. #Natera #ColonCancerAwareness

We are looking forward to presenting new data on Signatera™ at this year's American Society of Hematology Annual Meeting, Dec. 6–9 in Orlando, FL. See our presentation details below, including four abstracts that will highlight how our ctDNA technology is helping advance care for patients with hematologic malignancies. #ASH25 #Natera Learn more: https://ow.ly/SSy550Xyns6